To include your compound in the COVID-19 Resource Center, submit it here.

Metreleptin: Expanded access program data

An open-label, U.S. expanded access program of metreleptin in 9 patients with partial lipodystrophy showed that the compound reduced mean HbA1c from

Read the full 221 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE